Once-daily dose at the same time each day
No dosing differences with Lantus® (insulin glargine injection) 100 units/mL for insulin initiation1,2
Type 2 diabetes1 recommended starting dose
0.2 units/kg once daily or up to 10 units once daily
- Adjustments to the amount and timing of short- or rapid-acting insulins and dosages of any anti-diabetic medications may be necessary
Type 1 diabetes1 recommended starting dose
~1/3 of the total daily insulin requirements
- Short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements
- BASAGLAR must be used concomitantly with short-acting insulin
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.
Other dosing information
- Inject BASAGLAR subcutaneously once a day, any time of day, at the same time every day
- Individualize and titrate BASAGLAR dosage based on the metabolic needs, blood glucose monitoring results, and glycemic control goal of the individual
- Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function, and should be made under medical supervision with appropriate glucose monitoring
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.